ICONIC-LEAD phase III: Maintenance of response with icotrokinra in moderate-to-severe plaque psoriasis

During the European Academy of Dermatology and Venereology (EADV) Congress 2025, Jennifer Soung presented findings from the phase III ICONIC-LEAD trial (NCT06095115), evaluating maintenance of response with icotrokinra, a targeted oral peptide, in adult and adolescent patients with moderate-to-severe plaque psoriasis (PsO) (N = 684). At Week 24, adult responders (n = 341) were re-randomized to icotrokinra (n = 169) or placebo (n = 172). This analysis assessed Psoriasis Area and Severity Index (PASI) and Investigator’s Global Assessment (IGA) responses from Week 24 to Week 52 in adult responders and from Week 0 to Week 52 in adolescents.

Key data: Among adult Week 24 responders re-randomized to continuous icotrokinra, icotrokinra demonstrated superior maintenance of response compared with placebo: PASI 75 in 89% vs 30% (p < 0.001) and PASI 90 in 84% vs 21% (p < 0.001). In adolescents receiving continuous icotrokinra through Week 52, 95% achieved PASI 75, 86% achieved PASI 90, and 82% achieved IGA 0/1. The safety profile of icotrokinra through Week 52 was consistent with Week 16, with no new safety signals identified.

Key learning: Continuous icotrokinra treatment demonstrates superior maintenance of skin clearance response in adults with moderate-to-severe plaque PsO, with robust and durable responses through 52 weeks in both adults and adolescents, supporting its potential as an oral therapeutic option.